This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synageva BioPharma™ Initiates Dosing In Phase 3 Trial Of Sebelipase Alfa In Children And Adults With Late Onset LAL Deficiency

Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced that the first patient initiated treatment in the ARISE trial ( Acid Lipase Replacement Investigating Safety and Efficacy), a global, Phase 3, randomized, double-blind, placebo-controlled study of sebelipase alfa in children and adults with late onset lysosomal acid lipase deficiency (LAL Deficiency).

“The buildup of abnormal fats in LAL Deficiency can cause progressive and severe liver damage including cirrhosis in children and adults, as well as accelerated atherosclerosis,” said Anthony Quinn, MBChB, PhD, FRCP, Senior Vice President and Chief Medical Officer at Synageva. “By replacing the deficient enzyme that causes the accumulation of these abnormal fats, sebelipase alfa addresses the root cause of LAL Deficiency. Based on data from the previously conducted preclinical and clinical studies with sebelipase alfa, the Phase 3 ARISE trial was designed to assess the effects of sebelipase alfa on a broad range of abnormalities associated with LAL Deficiency.”

About ARISE: A global Phase 3 trial of sebelipase alfa in children and adults with late onset LAL Deficiency

The ARISE trial will enroll 50 patients (children and adults) with late onset LAL Deficiency. Patients enrolled in the trial are randomized on a one-to-one basis to every other week infusions of sebelipase alfa (1 mg/kg), or placebo for the double-blind treatment period of 20 weeks. Results from the double-blind period will be used to demonstrate efficacy and safety in support of global submissions for product registration. Patients who participate in the trial will qualify to enter a long-term, open-label extension period.

The primary endpoint of the trial is the proportion of patients relative to placebo who achieve normalization of alanine aminotransferase (ALT), a marker of liver damage, at the completion of the double-blind treatment period (week 20). Key secondary endpoints include the relative reduction from baseline to week 20 in LDL-C, non-HDL-C, triglycerides, the proportion of patients who achieve aspartate aminotransaminase (AST) normalization, and the relative increase in HDL-C. Additional secondary endpoints, including reductions in liver fat content and liver volume and improvements in liver pathology, will be examined in a proportion of patients who undergo these assessments. Deficiency of LAL enzyme activity will be confirmed during patient screening with a dried blood spot biochemical enzyme activity assay performed by Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the central diagnostic testing laboratory performing the tests.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs